Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance

Decoy Therapeutics Inc.

Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.
Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.
New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.
Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.
Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Decoy Therapeutics Inc.: Amended Certificate of Incorporation to effect a 1-for-12 reverse stock split of common stock (effective 2026-03-06).

Change: charter amendment
Effective: 2026-03-06

Exact text from the filing

On March 5, 2026, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.

View on SEC.gov

Browse all governance changes →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-092748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.